Overview

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

The goals of this study are: - to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) who have had one previous chemotherapy regimen that included a platinum containing drug such as cisplatin or carboplatin. - to assess response to treatment in patients with NSCLC six months after beginning study treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Pharmacyclics LLC.

Treatments:

Motexafin gadolinium
Pemetrexed